Compare VCEL & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | ENOV |
|---|---|---|
| Founded | 1989 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1996 | 2008 |
| Metric | VCEL | ENOV |
|---|---|---|
| Price | $32.94 | $24.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $57.75 | $47.38 |
| AVG Volume (30 Days) | 577.3K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.40 | $6.36 |
| Revenue Next Year | $18.24 | $5.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $28.95 | $21.00 |
| 52 Week High | $45.97 | $36.82 |
| Indicator | VCEL | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 49.23 |
| Support Level | $30.41 | $21.52 |
| Resistance Level | $34.77 | $27.11 |
| Average True Range (ATR) | 2.05 | 1.46 |
| MACD | -0.35 | 0.06 |
| Stochastic Oscillator | 12.24 | 39.49 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.